ReviewJournal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews2014
Toxicogenomics and cancer susceptibility: advances with next-generation sequencing.
Review in Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Is cancer the result of uncontrolled cellular growth? a glance into the tumorigenic process.Cancer cell international · 2026Review
- Global, Regional, and National Burden of Cancer in Children Younger Than 5 Years, 1990-2019: Analysis of the Global Burden of Disease Study 2019.Frontiers in public health · 2022Article
- Proteomics and its applications in breast cancer.American journal of cancer research · 2021Review
- Using FFPE RNA-Seq with 12 marker genes to evaluate genotoxic and non-genotoxic rat hepatocarcinogens.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2020Article
- Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics.Biochemical pharmacology · 2019Review
- Sequencing XMET genes to promote genotype-guided risk assessment and precision medicine.Science China. Life sciences · 2019Review
- Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis.Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews · 2019Article
- A functional SNP in the 3'-UTR of TAP2 gene interacts with microRNA hsa-miR-1270 to suppress the gene expression.Environmental and molecular mutagenesis · 2018Article
- A systematic evaluation of microRNAs in regulating human hepatic CYP2E1.Biochemical pharmacology · 2017Article
- Review of Ginkgo biloba-induced toxicity, from experimental studies to human case reports.Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews · 2017Review
- MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes.Biochemical pharmacology · 2016Article
- Aloe vera: A review of toxicity and adverse clinical effects.Journal of environmental science and health. Part C, Environmental carcinogenesis & ecotoxicology reviews · 2016Review
- Collaborative studies in toxicogenomics in rodent liver in JEMS·MMS; a useful application of principal component analysis on toxicogenomics.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2016Review
- Alignment of Short Reads: A Crucial Step for Application of Next-Generation Sequencing Data in Precision Medicine.Pharmaceutics · 2015Review
- MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.Biochemical pharmacology · 2015Article
- Obesity and genomics: role of technology in unraveling the complex genetic architecture of obesity.Human genetics · 2015Review
- Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.Scientific reports · 2015Article
- microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessment.Biomarkers in medicine · 2015Review
- Intersection of toxicogenomics and high throughput screening in the Tox21 program: an NIEHS perspective.International journal of biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aim of this review is to comprehensively summarize the recent achievements in the field of toxicogenomics and cancer research regarding genetic-environmental interactions in carcinogenesis and detection of genetic aberrations in cancer genomes by next-generation sequencing technology. Cancer is primarily a genetic disease in which genetic factors and environmental stimuli interact to cause genetic and epigenetic aberrations in human cells. Mutations in the germline act as either high-penetrance alleles that strongly increase the risk of cancer development, or as low-penetrance alleles that mildly change an individual's susceptibility to cancer. Somatic mutations, resulting from either DNA damage induced by exposure to environmental mutagens or from spontaneous errors in DNA replication or repair are involved in the development or progression of the cancer. Induced or spontaneous changes in the epigenome may also drive carcinogenesis. Advances in next-generation sequencing technology provide us opportunities to accurately, economically, and rapidly identify genetic variants, somatic mutations, gene expression profiles, and epigenetic alterations with single-base resolution. Whole genome sequencing, whole exome sequencing, and RNA sequencing of paired cancer and adjacent normal tissue present a comprehensive picture of the cancer genome. These new findings should benefit public health by providing insights in understanding cancer biology, and in improving cancer diagnosis and therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.